EMA Authorised: Catiolanze (Latanoprost) — Santen Oy

View source ↗

Summary

EMA authorises Catiolanze (latanoprost) for glaucoma, open-angle, indicating market entry by Santen Oy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glaucoma Open-angle

Drugs mentioned

• Catiolanze (latanoprost)

Snippet

Status: Authorised. Therapeutic area: Glaucoma, Open-Angle. MAH: Santen Oy. Decision date: 09/02/2024